Bay Harbor Wealth Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.96K Buy
25
+6
+32% +$409 ﹤0.01% 656
2026
Q1
$1.23K Buy
19
+8
+73% +$564 ﹤0.01% 696
2025
Q4
$740 Buy
11
+3
+38% +$202 ﹤0.01% 713
2025
Q3
$586 Buy
8
+2
+33% +$133 ﹤0.01% 672
2025
Q2
$312 Buy
6
+3
+100% +$171 ﹤0.01% 782
2025
Q1
$191 Buy
+3
New +$174 ﹤0.01% 689
2023
Q2
Sell
-49
Closed -$1.87K 171
2023
Q1
$1.87K Buy
+49
New +$2.3K ﹤0.01% 144
2021
Q1
Sell
-1,197
Closed -$51K 303
2020
Q4
$51K Hold
1,197
0.02% 160
2020
Q3
$31K Hold
1,197
0.02% 187
2020
Q2
$32K Hold
1,197
0.02% 185
2020
Q1
$22K Hold
1,197
0.01% 183
2019
Q4
$21K Hold
1,197
0.01% 199
2019
Q3
$19K Hold
1,197
0.01% 209
2019
Q2
$21K Sell
1,197
-303
-20% -$4.89K 0.01% 211
2019
Q1
$24K Hold
1,500
0.02% 218
2018
Q4
$22K Buy
+1,500
New +$23.9K 0.02% 217

Other funds holding HALO

Bay Harbor Wealth Management's HALO Position: Q2 2026 in Review

Bay Harbor Wealth Management increased its Halozyme (HALO) stake by 32% in Q2 2026, buying an estimated $409 and bringing the position to 25 shares worth $1.96K. The position accounts for ﹤0.01% of the portfolio, ranked #656.

Bay Harbor Wealth Management first reported a position in HALO in Q4 2018 and has held it in 16 quarters since. The position peaked at $51K in Q4 2020. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Bay Harbor Wealth Management held 25 shares of Halozyme worth $1.96K as of Q2 2026.
  • Bay Harbor Wealth Management bought 6 Halozyme shares in Q2 2026, an estimated $409.
  • Halozyme made up ﹤0.01% of Bay Harbor Wealth Management's portfolio in Q2 2026, its #656 holding.
  • Bay Harbor Wealth Management first reported a position in Halozyme in Q4 2018 and has held it in 16 quarters since.
  • Bay Harbor Wealth Management's Halozyme position peaked at $51K in Q4 2020.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Bay Harbor Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.